Dr. Lori Morton is the Director of Cardiovascular Research and Fibrosis Research at Regeneron Pharmaceuticals. In that role, Dr. Morton leads a team of scientists in the discovery and validation of new targets for the treatment of a wide variety of diseases affecting heart, kidney,lung and vascular function, as well as a number of diseases characterized by tissue scarring (fibrosis). Once interesting approaches to treat disease are identified, Dr. Morton’s group collaborates with a number of other research groups at Regeneron to develop and test newdrugs, determining the best drug candidates for new clinical programs.
Dr. Morton has a Bachelor or Arts degree in Biological Sciences from Douglass College of Rutgers University and a Ph.D. in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill. Following her Ph.D., Dr. Morton was a post-doctoral fellow at Pfizer Pharmaceuticals. As a Pfizer fellow, Dr. Morton then transferred to Memorial Sloan Kettering Cancer Center. In 2002, Dr. Morton joined Regeneron Pharmaceuticals in the Neuroendocrinology and Obesity Research group, and initiated cardiovascular studies to better understand the function of a number of genes and proteins on blood pressure, cardiac and renal function. These efforts have grown into the present Cardiovascular Research department.
Dr. Morton is also on the Board of Directors of the Chappaqua Children’s Book Festival and is the current Chair of the Chappaqua PTA STEM Committee. Dr. Morton has been a member of the American Heart Association for 11 years.